JPRN-jRCT2080225293
Completed
Phase 1
An Open-label Study to Assess the Safety and Tolerability of a Single Dose of S-600918 (Part 1) and a Randomized, Double-blind, Placebo- and Positive-controlled, 4-Period Crossover, Thorough QT/QTc Study of S-600918 (Part 2) in Healthy Adult Participants
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- SHIONOGI & CO., LTD.
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy subjects
Exclusion Criteria
- •Subjects who are considered ineligible for this study by the investigator or subinvestigator due to current or history of significant metabolic or endocrine, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, immune, neurological or psychiatric disorders, or other clinically significant diseases.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
An Open Label Study Assessing the Safety and Tolerability of SB206 in Japanese subjects with Molluscum ContagiosumJPRN-jRCT2031230123Yoshiyuki Kaneko20
Active, not recruiting
Not Applicable
Open-Label Safety Study of MF/F in AsthmaPersistent AsthmaTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-004583-38-Outside-EU/EEASchering-Plough Research Institute, a division of Schering Corporation49
Completed
Phase 1
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Dapagliflozin 70 mg Extended Release Capsules in Healthy VolunteersACTRN12620001187932ovotech (Australia) Pty Limited10
Terminated
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Dapagliflozin Extended Release Capsules in Healthy Volunteers.ACTRN12619001577101yndra Australia Pty Ltd44
Completed
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Rosuvastatin Extended Release CapsulesACTRN12621000101886yndra Therapeutics, Inc. (Lyndra)16